Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Atzheimer's disease

Neuroendocrinology Letters

Volumn 21, Issue 1, 2000, Pages 39-42

  Brusco, Luis I ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Alzheimer's disease; Antioxidants; Cognitive impairment; Melatonin; Sleep disorders

Indexed keywords

ALLOPURINOL; ALPHA TOCOPHEROL; ALPRAZOLAM; ATENOLOL; CLOZAPINE; ENALAPRIL; LEVODOPA; MELATOL; MELATONIN; NIFEDIPINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN CORTEX; CHRONOBIOLOGY; CLINICAL ARTICLE; COGNITIVE DEFECT; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; RETROSPECTIVE STUDY; SLEEP DISORDER; TEMPORAL CORTEX;

EID: 0033994649     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Pappolla M, Bozner P, Soto C, Shao H, Robakis NK, Zagorski M, et al. Inhibition of Alzheimer β-fibrillogenesis by melatonin. J Biol Chem 1998; 273:7185-7188.
2. Daniels WM, Van Rensburg SJ, Van Zyl JM, Taljaard JJ. Melatonin prevents β amyloid, induced lipid peroxidation. J Pineal Res 1998; 24:78-82.
3. Song W, Lahiri K. Melatonin alters the metabolism of the β-amyloid precursor protein in the neuroendocrine cell line PC12. J Mol Neurosci 1997; 9:75-92.
4. Bozner P, Grishko V, Ledoux SP, Wilson GL, Chyan YC, Pappolla MA. The amyloid -protein induces oxidative damage of mitochondrial DNA. J Neuropathol Exp Neurol 1997; 56:1356-1362.
5. Fainstein I, Bonetto A3, Brusco LI, Cardinali DP. Effects of melatonin in elderly patients with sleep disturbance. A pilot study. Current Ther Res 1997; 58:990-1000.
6. Brusco LI, Marquez M, Cardinali DP. Monozygotic twins with Alzheimer's disease treated with melatonin. Case report. J Pineal Res 1998; 25:260-263.
7. Kaplan HI, Sadock BJ, Grebb JA. Synopsis of psychiatry, 7th ed. Baltimore: Williams & Wilkins; 1994.
8. Auer S, Reisber B. The GDS/FAST staging system. Int Psychogeriatr 1997; 9 Suppl 1:167-171.
9. Mohs RC, Cohen L Alzheimer's disease assessment scale (ADAS). Psychopharmacol Bull 1988; 24:627-628.
10. Mattis S. Dementia rating scale professional manual, Psychological Assessment Resources: Odess, FLA; 1988.
11. Blessed G, Tomlinson BE, Roth M. Blessed-Roth dementia scale (DS). Psychopharmacol Bull 1988; 24:689-692.
12. Katzman R, Kawas C. The epidemiology of dementia and Alzheimer Disease. In: Terry RD, Katzman R, Bick KL, editors. Alzheimer disease, New York: Raven Press; 1994. p. 105-122.
13. Jost BC, Grossberg GT. The evolution of the psychiatric symptoms in Alzheimer's disease: A natural history study. J Am Geriatr Soc 1996; 44:1078-1081.
14. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donazepil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8:67-75.
15. McGaffiganS, Bliwise DL. The treatment of sundowning: A selective review of pharmacological and nonpharmacological studies. Drugs & Aging 1997; 10:10-17.
16. Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DL, Reiter RJ, et al. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 1997; 17:1683-1690.
17. Reiter RJ, Tang L, Garcia JJ, Munoz Hoyos A. Pharmacological actions of melatonin in oxygen radical pathophysiology. Life Sei 1997; 60:225-271.
18. Kotler M, Rodriguez C, Sainz RM, Antolin I, Menéndez PelaezA. Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J Pineal Res 1998; 24:83-89.